Herantis Pharma Oyj (HRPMF) Discusses Phase 1b Biomarker Data for HER-096 in Parkinson's Disease and Implications for Clinical Development Transcript

PresentationAntti VuolantoChief Executive Officer Hello, and welcome to Herantis Pharma's Phase Ib Biomarker Data webinar. I am CEO, Antti Vuolanto, joined today by CSO, Henri Huttunen; and CFO, Tone Kvale. We are really excited to discuss yesterday evening's announced biomarker data for HER-096, our lead asset currently in development for the treatment of Parkinson's disease. These data present a significant milestone for the company, providing evidence of biological response to HER-096 dosing in humans wi ...